Last reviewed · How we verify
NCT06751069
Home-based Pulmonary Rehabilitation and Health Coaching in Patients With Fibrotic Interstitial Lung Disease
NA trial testing Home-based Pulmonary Rehab in Lung Fibrosis in 460 participants. Currently enrolling.
1 July 2030
Quick facts
| Lead sponsor | Mayo Clinic |
|---|---|
| Phase | NA |
| Status | Recruiting now |
| Study type | INTERVENTIONAL |
| Allocation | randomized |
| Design | parallel |
| Masking | none |
| Primary purpose | treatment |
| Enrollment | 460 |
| Start date | 3 March 2025 |
| Primary completion | 1 July 2030 |
| Estimated completion | 30 September 2030 |
| Sites | 4 locations across United States |
Drugs / interventions tested
- Home-based Pulmonary Rehab
Conditions studied
- Lung Fibrosis — all drugs for Lung Fibrosis →
- Lung Interstitial Disease — all drugs for Lung Interstitial Disease →
Sponsor
Mayo Clinic
Who can join
18 and older, any sex, with Lung Fibrosis or Lung Interstitial Disease. Patients with the condition only — healthy volunteers not accepted.
Sponsor's own description
The purpose of this clinical trial is to determine the impact of a home-based pulmonary rehabilitation program with health coaching on patient-reported respiratory-related quality of life and physical activity, as compared to usual care in patients with fibrotic interstitial lung disease.
Publications & conference data
1 peer-reviewed publication reference this trial (live from Europe PMC):
-
Home-based rehabilitation in interstitial lung disease: picturing the present and drawing the future through a systematic review of the literature.
Bongiovanni G, Polelli V, Stainer A, Russo M, et al · · 2026 · PMID 42111388 · DOI 10.1183/23120541.00879-2025
Verify or expand the search:
- PubMed search for NCT06751069
- Europe PMC full search
- ASCO Meeting Library
- ESMO Meeting Library
- bioRxiv preprints
- medRxiv preprints
- Google Scholar
Related trials
Other recruiting trials for Lung Fibrosis
Currently open trials in the same condition.
- NCT07236541 — Impact of Airway Mucus Plugs on Secondary Pulmonary Fibrosis in COPD Patients: A Single-Center Case-Control Study · recruiting
- NCT07088185 — Pulmonary Outcomes on Patients With Lung Fibrosis · NA · active not recruiting
- NCT06189820 — Role of the Fibroblast Activation Protein (FAP) as Biomarker of Fibrotic Lung Diseases · Phase 2 · recruiting
- NCT05382572 — Pulmonary Fibrosis Foundation Community Registry · recruiting
- NCT05191381 — Immune Modulation by Exosomes in COVID-19 · recruiting
Other Mayo Clinic trials
Trials by the same sponsor.
- NCT07126548 — A Point of Prostate Cancer Diagnosis Virtual Reality Assistant Intervention in Supporting Newly Diagnosed Black Men · NA · not yet recruiting
- NCT07221656 — Evaluation of Prolonged Asparaginase Activity Levels After Calaspargase Pegol Administration · not yet recruiting
- NCT06891001 — The Utilization of a Shoe Insert on Individuals With Unilateral Greater Trochanteric Pain Syndrome on Single Leg Stance, · NA · not yet recruiting
- NCT07169799 — Impact of Cryotherapy Spray (Tru-Freeze) for the Eradication of Gastric Antral Vascular Ectasia (ICE-GAVE) · NA · recruiting
- NCT07086183 — Perioperative Risk in Patients on Chronic Aspirin Undergoing Craniotomy · not yet recruiting
Verify against primary sources
- ClinicalTrials.gov — authoritative US registry record
- WHO ICTRP — international registry index
- EU Clinical Trials Register
- Sponsor press releases (Google)
- Trial protocol + status: ClinicalTrials.gov NCT06751069 (US National Library of Medicine, public domain)
- Publications: Europe PMC API search by NCT ID, retrieved 10 June 2026
- Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
- Sponsor: as reported to ClinicalTrials.gov by Mayo Clinic
- Last refreshed: 20 March 2026
Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT06751069.
Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing